NICE recommends Xofigo (radium Ra 223 dichloride) for treatment of hormone relapsed metastatic prostate cancer- Bayer HealthCare
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal for Xofigo (radium Ra 223 dichloride) from Bayer HealthCare and recommended use of the drug as a treatment for adults with prostate cancer which has stopped responding to hormone therapy (known as hormone relapsed) and has spread to the bone (bone metastases). This is an option for treating adult men with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.